Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMIT-UC: Mirikizumab + Tirzepatide in Ulcerative Colitis and Obesity
NCT06937086Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
A Phase 3 trial of tirzepatide in ulcerative colitis (UC), obesity, sponsored by Eli Lilly and Company. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
ulcerative colitis (UC)obesity
Beyond the preview
Go deeper on NCT06937086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937086.